manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa

More documents

Recommendations

Info

183. Casato M, Agnello V, Pucillo LP et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865–73 184. Cacoub P, Lidove O, Maisonobe T et al. Interferon- and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317–26 185. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. Scand J Rheumatol 2000;29:201–2 186. Safadi R, Shouval D, Kaspa RT, Ashur Y, Llan Y. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. Liver Transpl Surg 1996;2:263–8 187. Hibbs, J.R. et al, Aplastic Anemia and Viral Hepatitis, JAMA, 1992;267(15):2051-2054 188. Pol, S. Et al, Lack of evidence for a role of HCV in hepatitis-associated aplastic anaemia, Brit J of Haem, 85(4):808-810 189. Rockstroh JK, Spengler U, Sundho T et al. Immuno-suppression may lead to progression of hepatitis C virus (HCV) associated liver disease in HIV–HCV co-infected hemophiliacs. Am J Gastroenterol 1996;91:2563–8 190. Pockros, P.J., New drugs for HCV, Expert Review of Gastroenterol and Hepatol, Oct 2007, 1(1): 145-154 191. Weitz I.C, Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab, Am J of Hematol, Febr.2005, 78(2):138-141 192. de Vita, S, Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia, Blood Sept1995, 86(5)1887-1892 193. Collier J.D.et al, No association between hepatitis C and B-cell lymphoma, Hepatol, Apr.1999, 29(4):1259-1261 194. Zuckerman E et al, Hepatitis C Virus Infection in Patients with B-Cell Non-Hodgkin Lymphoma, Ann of Int Med, Sept1997,127(6): 423-428 195. Ferri C. et al, Hepatitis C virus infection in patients with non-Hodgkin's lymphoma, Brit J of Haematol,Oct 1994,88(2):392-394 196. Vallisa D et al, Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV- Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience, J of Clin Oncol, Jan 2005, 23(3):468-473 197. Mele A et al, Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study, Neoplasia, Aug 2003, 100(3):996-999 198. Prieta J. et al, Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom, Hepatol, Febr 1996 , 23(2):199-204 199. Munoz-Rodriguez, F.J.et al, Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome, J of Hepatol, May 1999, 30(5):770-773 200. Gocke D.J.et al, Association between Polyarteritis and australia Antigen, The Lancet, Dec. 1970, 296(7684):1149-1153
201. Trepo C, Guillevin L, Polyarteritis Nodosa and Extrahepatic Manifestations of HBV Infection: The Case Against Autoimmune Intervention in Pathogenesis, J of Autoimm, Mar 2002, 16(3):269-274 202. Guillevin, L et al, Polyarteritis Nodosa Related to Hepatitis B Virus: A Prospective Study with Long-Term Observation of 41 Patients, Medicine, Sept 1995, 74(5):238-253 203. Trepo C.G, The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa, Clin Pathol 1974;27:863-868 204. Guillevin L, Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients, J Rheumatol. 1993 Feb;20(2):289- 98 205. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges, Ann Rheum Dis 1994;53:334-337 206. Lai, K.N et al, The Clinico-pathologic Features of Hepatitis B Virusassociated Glomerulonephritis, QJM (1987) 63 (1): 323-333 207. Shapiro J et al, Remission of Nephrotic Syndrome of HBV-Associated Membranous Glomerulopathy following Treatment with Interferon, Am J Nephrol 1995;15:343-347 208. Connor, F.L, HBV associated nephrotic syndrome: resolution with oral lamivudine, Arch Dis Child 2003;88:446-449 209. Baig S, The Extrahepatic Manifestations of Hepatitis B Virus, J Coll Physicians Surg Pak, 2008, 18 (7): 451-457 210. Galli M et al, Hepatitis B virus-related markers in secondary and in essential mixed cryoglobulinemias: a multicentric study of 596 cases. The Italian Group for the Study of Cryoglobulinemias (GISC), Ann Ital Med Int. 1992 Oct- Dec;7(4):209-14 211. Pyrsopoulos N, Extrahepatic manifestations of chronic viral hepatitis, Current Gastroenterol Rep, 3(1), 71-78 212. McElguun, PSJ, Dermatologic manifestations of hepatitis B virus infection, JAAD 8(4),April 1983, 539-548 213. Caputo R et al, Gianotti-Crosti syndrome: a retrospective analysis of 308 cases, JAAD, Febr. 1992,26(2):207-210 214. Csepregy A, et al, Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link, J of Rheumatol, 28(3),474-477 215. Li,S et al, Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients, Clin Rheumat, Volume 28, Number 7, July 2009 , pp. 787-791(5) 216. Girard M, Autoimmune hazards of hepatitis B vaccine, Autoimmunity Reviews 4(2), Febr 2005:96-100 217. Nyu, M et al, Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System, Ped Inf Dis J, Sept1996,15( 9):771-776
Page 1 and 2:
UNIVERSITATEA DE MEDICINĂ ŞI FARM
Page 3 and 4:
II.2.6 Afectarea neurologică 45 II
Page 5 and 6:
STADIUL CUNOAŞTERII ACTUALE MANIFE
Page 7 and 8: fenomenelor autoimune concomitente.
Page 9 and 10: Afectarea cerebrală Multe din stud
Page 11 and 12: cardiomiopatii hipertrofice şi 33,
Page 13 and 14: fost citată mai ales în America d
Page 15 and 16: şi complement, dar şi crioprecipi
Page 17 and 18: sunt secundare hepatopatiilor croni
Page 19 and 20: PARTEA PERSONALĂ STUDIUL I. MANIFE
Page 21 and 22: Tabelul.5.III. Distribuţia cazuril
Page 23 and 24: Fig.5.10. Repartiţia cazurilor în
Page 25 and 26: Tabelul 5.XXX. Parametrii estimaţi
Page 27 and 28: Valorile colesterolului în dinamic
Page 29 and 30: Tabelul 5.LXXXVIII Estimarea parame
Page 31 and 32: Corelaţie parţială fost calculat
Page 33 and 34: EVALUAREA CALITĂŢII VIEŢII LA CO
Page 35 and 36: DISCUŢII 1. Stabilirea tipului, in
Page 37 and 38: sau dobândită, ar trebui testaţi
Page 39 and 40: De asemeni, leucopeniile s-au asoci
Page 41 and 42: la două ore, date care sunt în co
Page 43 and 44: demonstrează o asociere moderată
Page 45 and 46: CONCLUZII 1. Profilul pacientului p
Page 47 and 48: 26. Exacerbarea manifestărilor aut
Page 49 and 50: 34. Iashina TL, Favorov MO, Shakhgi
Page 51 and 52: 66. Zuckerman J, van Hattum J, Caff
Page 53 and 54: 99. Gish G. R., et al, Safety and a
Page 55 and 56: 134. Simsek H, Savas C, Akkiz H, Te
Page 57: 167. Quaranta JF, Tran A, Regnier D
Page 61: 235. Moriya K, Nakgawa K, Santa T,
show all

manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa

Create successful ePaper yourself

Delete template?

Save as template?